1262 studies found for:    LEUKEMIA, CHRONIC MYELOID
Show Display Options
Rank Status Study
1 Recruiting Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
Condition: Leukemia, Chronic Myeloid
Interventions: Drug: Pioglitazone;   Other: imatinib discontinuation
2 Completed
Has Results
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib
3 Completed
Has Results
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Intervention: Drug: Dasatinib
4 Completed
Has Results
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Conditions: Leukemia;   Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia
Intervention: Drug: Interleukin-11 (IL-11 or Neumega)
5 Completed PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Intervention: Drug: bortezomib
6 Completed
Has Results
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: triapine;   Procedure: laboratory biomarker analysis
7 Terminated Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: temsirolimus;   Other: laboratory biomarker analysis
8 Completed Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: decitabine;   Other: laboratory biomarker analysis
9 Not yet recruiting Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia;   Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Questionnaire Administration
10 Completed Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: oblimersen sodium;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis
11 Completed Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Completed STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: cytarabine
13 Completed Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
Condition: Chronic Myeloid Leukemia
Intervention: Biological: Autologous CIK cell infusion
14 Terminated Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: dasatinib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: cyclosporine
15 Completed Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
17 Completed Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, interferon-alfa
18 Active, not recruiting Patient Reported Outcomes in Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: HRQOL questionnaire
19 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
20 Not yet recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years